Efficacy and safety of iodopovidone pleurodesis in malignant pleural effusions |
| |
Authors: | Jose D.A. NETO Sandro F.Q. de OLIVEIRA Sylvana P. VIANNA AND Ricardo M. TERRA |
| |
Affiliation: | Department of Thoracic Surgery of Hospital Aristides Maltez, Salvador, BA, and;Division of Thoracic Surgery, Hospital das Clinicas, University of São Paulo Medical School, São Paulo, SP, Brazil |
| |
Abstract: | Background and objective: Pleurodesis is one of the best methods of controlling malignant pleural effusions (MPE), a distressing complication of metastatic disease. In recent studies of a wide range of pleural diseases, iodopovidone was used as a sclerosing agent for pleurodesis and demonstrated good results with low morbidity. The aim of this study was to evaluate the efficacy and safety of iodopovidone pleurodesis in MPE. Methods: A retrospective analysis was performed on patients with MPE who underwent pleurodesis at our institution between 2005 and 2008. All patients underwent instillation of 20 mL of 10% iodopovidone, 80 mL of normal saline and 2 mg/kg of lidocaine through a chest tube, which was clamped for 2 h. The tube was removed when the daily output of fluid was <200 mL. Data on the requirement for additional pleural procedures, adverse events and survival were collected. Results: Sixty‐one pleurodesis procedures were performed in 54 patients. No procedure‐related mortality was observed. Adverse events occurred after 11 (18%) pleurodesis procedures. The most frequent complication was mild thoracic pain that occurred immediately after 10 (16.4%) procedures, and one patient developed pleural empyema that was treated with drainage and antibiotics. A success rate of 98.4% was observed. Except for the patient who developed pleural empyema, none of the other patients had recurrences of pleural fluid or required additional pleural procedures during the follow‐up period (mean of 5.6 months). Conclusions: Iodopovidone pleurodesis was successful and was associated with only a few minor complications. It appears to be a good option for the management of recurrent MPE. |
| |
Keywords: | efficacy iodopovidone malignant pleural effusion pleurodesis safety |
|
|